Coherus discussed the commercial launch of LOQTORZI in nasopharyngeal carcinoma (NPC), describing the indication as an area of unmet need where, according to management, there had not been a labeled option prior to LOQTORZI. The company estimated approximately 2,000 patients per year and said patients historically were treated with chemotherapy or potentially off-label immuno-oncology agents.Leadership also described the transformation as extending beyond assets and strategy to include changes in the team, ...